Wisconsin Alumni Research Foundation (WARF)
Edit

Wisconsin Alumni Research Foundation (WARF)

https://warf.org/
Last activity: 21.10.2025
Active
Categories: FinTechInvestmentMarketplaceMedTechMovingNonprofitResearchScienceTechnologyUniversity
As the designated patenting and licensing organization for the University of Wisconsin–Madison, the Wisconsin Alumni Research Foundation (WARF) advances transformative discoveries to the marketplace to benefit humankind across Wisconsin and the world.

Our vision is to enable UW–Madison research to solve the world’s problems. We support scientific research within the UW community by providing financial support, actively managing assets and moving innovations to the market for a financial return and global impact.

Three strategic programs support our efforts. WARF Accelerator provides business resources and targeted funding to help inventors advance commercially promising technologies closer to the marketplace. WARF Therapeutics partners with inventors working on translational research to develop and commercialize novel drug-like molecules. And, WARF Ventures works to advance technologies by investing in select startup companies within the UW community.

Founded in 1925 by visionary alumni, WARF is a nonprofit, mission-driven organization that is among the oldest and most successful technology transfer offices in the nation. For more than 90 years, we've invested in research to make a difference.
Likes
932
Followers
5.79K
Website visits
14.4K /mo.
Mentions
46
Location: United States, Wisconsin, Madison
Employees: 51-200
Phone: +1 608-263-2500
Founded date: 1925

Mentions in press and media 46

DateTitleDescription
21.10.2025WARF Board Welcomes New Trustee Judy OlianJudy Olian MADISON, WI, UNITED STATES, October 21, 2025 /EINPresswire.com/ -- The Wisconsin Alumni Research Foundation is proud to announce the appointment of Judy D. Olian, a distinguished leader in higher education and management, to its ...
24.09.2025Immuto Scientific Secures $8M, Unlocks New Era in Precision Drug DiscoveryImmuto Scientific, a biotechnology pioneer, has significantly advanced its mission. The company closed an oversubscribed $8 million Seed 2 financing round. This critical capital fuels its proprietary AI-enabled structural surfaceomics platf...
22.09.2025Immuto Scientific: $8 Million Raised For Advancing New Class Of Therapeutic Targets With Structural SurfaceomicsImmuto Scientific has closed an oversubscribed Seed 2 financing round, raising a total of $8 million. The company has also announced a collaboration with Daiichi Sankyo, a well-known global pharmaceutical company. Immuto is utilizing its un...
18.09.2025Immuto Scientific Raises $8M in Seed 2 FinancingImmuto Scientific, a Madison, WI-based biotechnology company developing an AI‑enabled target discovery platform, raised $8M in Seed 2 funding. The round was led by DYDX, with participation from WARF Ventures, Gravity Fund, Great Oaks Ventur...
18.06.2025Strategic Governance Fuels WARF's Next Century of InnovationAs WARF marks its centennial, a new essay by Board Chair Deborah Keller and CEO Erik Iverson highlights how strategic governance has transformed the foundation’s Board into a driving force for innovation. MADISON, WI, UNITED STATES, June 18...
03.06.2025Infleqtion's Quantum Leap: $100 Million to Revolutionize TechnologyIn the heart of Boulder, Colorado, a quantum revolution is brewing. Infleqtion, a company born from the academic halls of the University of Colorado, has just secured a staggering $100 million in Series C funding. This infusion of capital i...
02.06.2025Quantum startup Infleqtion eyes defense industry applications after raising $100M Your vote of support is important to us and it helps us keep the content FREE. One click below supports our mission to...Infleqtion Inc. said today it has raised $100 million from a host of venture capital investors and the government services contractor Science Applications International Corp. to accelerate the development of its neutral atom-based quantum c...
02.06.2025Infleqtion closes $100M Series C roundInfleqtion, a quantum technology company that uses lasers to maintain those systems, has fetched roughly $100 million in Series C capital from investors to aid in the further development and scaling of its product offerings. Founded as cold...
31.03.2025Hubble Therapeutics: $7.3 Million (Series A) Raised For Developing Gene Therapy Cure For LCA16Hubble Therapeutics, a patient-focused biotechnology company developing a gene therapy to cure pediatric blindness, announced the closing of a $7.3 million Series A funding round, which will advance its lead candidate, HUB-101, into human c...
26.03.2025Hubble Therapeutics: A New Dawn for Pediatric BlindnessIn the world of biotechnology, every breakthrough feels like a ray of hope piercing through a dark cloud. Hubble Therapeutics, a Hanover, NH-based company, has recently secured $7.3 million in Series A funding. This financial boost is not j...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In